Cargando…

Screening for HCV infection combined with SARS-CoV-2 vaccination in the Campania region

Detalles Bibliográficos
Autores principales:	Torre, Pietro, Masarone, Mario, Sciorio, Roberta, Annunziata, Monica, Coppola, Roberta, Staiano, Laura, Coppola, Carmine, Persico, Marcello
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Association for the Study of the Liver. Published by Elsevier B.V. 2022
Materias:	POSTER PRESENTATIONS: Friday 24 June: Viral hepatitis C: Clinical aspects except therapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252364/ http://dx.doi.org/10.1016/S0168-8278(22)01424-6

Ejemplares similares

Hepatitis C treatment during the COVID-19 pandemic has similar efficacy with less resource utilization: analysis from the British Columbia HCV network
por: Jiang, Shirley, et al.
Publicado: (2022)

Screening for HCV infection combined with SARS-CoV-2 vaccination in the Campania region
por: Torre, P., et al.
Publicado: (2022)

Hepatitis C screening during SARS‐CoV‐2 testing or vaccination. Experience in an area of southern Italy in the province of Salerno
por: Torre, Pietro, et al.
Publicado: (2022)

Histological changes in HCV antibody–positive, HCV RNA–negative subjects suggest persistent virus infection
por: Hoare, Matthew, et al.
Publicado: (2008)

HCV disease burden and population segments in Switzerland
por: Bihl, Florian, et al.
Publicado: (2021)

Mucosal‐associated invariant T‐cell frequency and function in blood and liver of HCV mono‐ and HCV/HIV co‐infected patients with advanced fibrosis
por: Beudeker, Boris J. B., et al.
Publicado: (2017)

Epidemiological trends in HCV transmission and prevalence in the Viennese HIV+ population
por: Schmidbauer, Caroline, et al.
Publicado: (2020)

Forecasting Hepatitis C liver disease burden on real‐life data. Does the hidden iceberg matter to reach the elimination goals?
por: Kondili, Loreta A., et al.
Publicado: (2018)

Chronic Hepatitis C Virus (HCV) Disease Burden and Cost in the United States
por: Razavi, Homie, et al.
Publicado: (2013)

Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin
por: Feld, Jordan J., et al.
Publicado: (2018)

Long‐term follow‐up of clinical trial patients treated for chronic HCV infection with daclatasvir‐based regimens
por: Reddy, K. Rajender, et al.
Publicado: (2017)

SNP rs688 within the low‐density lipoprotein receptor (LDL‐R) gene associates with HCV susceptibility
por: Steba, Gaby S., et al.
Publicado: (2018)

Adherence to pan‐genotypic glecaprevir/pibrentasvir and efficacy in HCV‐infected patients: A pooled analysis of clinical trials
por: Brown, Ashley, et al.
Publicado: (2019)

Peripheral neuropathy after viral eradication with direct‐acting antivirals in chronic HCV hepatitis: A prospective study
por: Zanone, Maria M., et al.
Publicado: (2021)

Feasibility and effectiveness of HCV viraemia testing at harm reduction sites in Georgia: A prospective three‐arm study
por: Shilton, Sonjelle, et al.
Publicado: (2022)

Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies
por: Yao, Betty B., et al.
Publicado: (2020)

Country-Wide HCV Elimination Strategies Need to Reach Older Patients in the General Population: The Italian Experience
por: Torre, Pietro, et al.
Publicado: (2023)

Associated screening for HCV and SARS‐Cov2 infection in an urban area of Southern Italy: A cohort study
por: Coppola, Carmine, et al.
Publicado: (2021)

Hepatitis C virus transmission among human immunodeficiency virus‐infected men who have sex with men: Modeling the effect of behavioral and treatment interventions
por: Salazar‐Vizcaya, Luisa, et al.
Publicado: (2016)

Estimating the Net Contribution of Interleukin-28B Variation to Spontaneous Hepatitis C Virus Clearance
por: di Iulio, Julia, et al.
Publicado: (2011)

Expression of Paramyxovirus V Proteins Promotes Replication and Spread of Hepatitis C Virus in Cultures of Primary Human Fetal Liver Cells
por: Andrus, Linda, et al.
Publicado: (2011)

Effect of Immune Pressure on Hepatitis C Virus Evolution: Insights From a Single-Source Outbreak
por: Merani, Shahzma, et al.
Publicado: (2011)

Transcriptome Sequencing, Microarray, and Proteomic Analyses Reveal Cellular and Metabolic Impact of Hepatitis C Virus Infection In Vitro
por: Woodhouse, Stephen D, et al.
Publicado: (2010)

IFITM1 is a tight junction protein that inhibits hepatitis C virus entry,
por: Wilkins, Courtney, et al.
Publicado: (2013)

Liver-primed CD8(+) T cells suppress antiviral adaptive immunity through galectin-9-independent T-Cell immunoglobulin and mucin 3 engagement of high-mobility group box 1 in mice
por: Dolina, Joseph S, et al.
Publicado: (2014)

Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load
por: Gordon, Stuart C, et al.
Publicado: (2013)

Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals
por: Martin, Natasha K, et al.
Publicado: (2013)

Paracrine Signals From Liver Sinusoidal Endothelium Regulate Hepatitis C Virus Replication
por: Rowe, Ian A, et al.
Publicado: (2014)

Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus
por: van de Ven, Nikolien, et al.
Publicado: (2015)

Branched-chain amino acids reduce hepatic iron accumulation and oxidative stress in hepatitis C virus polyprotein-expressing mice
por: Korenaga, Masaaki, et al.
Publicado: (2015)

DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection
por: Burza, Maria Antonella, et al.
Publicado: (2015)

Safety and efficacy of ledipasvir‐sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data
por: Wilder, Julius M., et al.
Publicado: (2015)

Flunarizine prevents hepatitis C virus membrane fusion in a genotype‐dependent manner by targeting the potential fusion peptide within E1
por: Perin, Paula M., et al.
Publicado: (2015)

Antibodies to an interfering epitope in hepatitis C virus E2 can mask vaccine‐induced neutralizing activity
por: Kachko, Alla, et al.
Publicado: (2015)

Structure-Guided Design Affirms Inhibitors of Hepatitis C Virus p7 as a Viable Class of Antivirals Targeting Virion Release
por: Foster, Toshana L, et al.
Publicado: (2014)

Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C
por: Tsochatzis, Emmanuel A, et al.
Publicado: (2014)

Type I interferon rapidly restricts infectious hepatitis C virus particle genesis
por: Meredith, Luke W, et al.
Publicado: (2014)

Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP)
por: Watashi, Koichi, et al.
Publicado: (2014)

Chronic hepatitis C viral infection subverts vaccine‐induced T‐cell immunity in humans
por: Kelly, Christabel, et al.
Publicado: (2016)

Estimation of hepatitis C virus infections resulting from vertical transmission in Egypt
por: Benova, Lenka, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ogh5r690oucsdedqjmn7cil3vr